David Ricks, Chair and CEO of Eli Lilly, joins Scott to discuss the rise of GLP-1 drugs, the future of obesity treatment, and why America's healthcare system is facing a crisis of trust. They explore healthcare costs, addiction, unregulated peptides, pharmaceutical innovation, and the role AI could play in the next generation of drug discovery.
Want to listen to this and other episodes ad-free? You can, if you subscribe at profgmedia.com.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
